10th International Congress on Targeted Therapies Is on the Cutting Edge

Published Online: Tuesday, August 21, 2012
Follow Pharmacy_Times:
Plainsboro, N.J. – Aug. 20, 2012 – The go-to source for excellence in continuing medical education, Physicians’ Education Resource (PER), hosted the 10th International Congress on Targeted Therapies in Cancer® this past weekend, Aug. 17—18, at the Mayflower Renaissance Hotel in Washington, D.C.
In this new age of cancer drugs, therapies that are based on targeting specific molecular pathways or specific cell types have moved from the bench into clinical practice. Understanding what lies on the horizon in this rapidly evolving environment is critical. The International Targeted Therapies Congress, conducted by key leaders in the field, is designed to provide cutting-edge information on novel, targeted anticancer therapies now in development, including the most current clinical data on those agents and their mechanisms of actions.  The educational program is directed toward medical oncologists, hematologists, drug developers, translational researchers, and other health care professionals interested in the management of cancer.
The congress was chaired by Alex A. Adjei, MD, PhD, Senior Vice President of Clinical Research, Professor and Chair for the Department of Medicine at Roswell Park Cancer Institute in Buffalo, New York, and John Wright, MD, PhD, Associate Chief of the Investigational Drug Branch at the National Cancer Institute in Bethesda, Maryland.
The congress provided unique opportunities for participants to learn from, and interact with, leaders in the field, evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of cancer, and apply clinical trial data appropriately in order to optimize patient outcomes.
Faculty presentations addressed the challenges and opportunities for targeted therapy as well as provided a first-hand preview into the next generation of cancer therapy. Several question and answer sessions were offered, enabling participants to speak with leading researchers on topics such as imaging tumor response and therapeutic vaccines in cancer.
PER is accredited by the Accreditation Council for Continuing Medical Education to provide learning opportunities for physicians. Incorporating instructional design with principles of adult learning, PER plans, develops, implements and evaluates educational opportunities, including multi-day congresses, one-day update conferences, regional meetings, online case discussions, and faculty dialogues. These educational activities enable health care professionals to remain current and responsive to advances in medical care for cancer patients, from diagnosis through treatment, with the ultimate goal of improving patient outcomes.
To learn more, visit www.gotoper.com.
About Physicians’ Education Resource, LLC
Accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource (PER) is the certified medical education resource of choice for live and online activities focusing on oncology and hematology. Based on identified needs and practice gaps, PER provides high-quality, evidence- based activities featuring leading national and international faculty with a focus on practice changing advances and standards of care in treatment and disease management. PER serves the oncology health care community, including physicians, fellows, physician assistants, advanced practice nurses, nurses, pharmacists, and researchers. Learn more at www.gotoper.com.
Media Contact:
Kaytlynn Gorson
For Physicians’ Education Resource
267-932-8760 Ext.300
Related Articles
Celgene today announced that the FDA has granted an expanded use approval for its multiple myeloma drug, lenalidomide (Revlimid).
Although testosterone is often considered to be a catalyst of prostate cancer, a recent study suggests that the hormone may be able to subdue advanced prostate cancer and break down resistance to testosterone-blocking drugs used to treat the disease.
A vaccine therapy that stimulates the body’s own immune defenses is safe to give to prostate cancer patients early in the disease’s progression, a recent study found.
Researchers have developed a personalized genetic test that can accurately predict the risk for recurrence in prostate cancer patients.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times